Press Releases

BioCardia announces completion of two year follow-up for patients enrolled in the TABMMI trial. Enrollment of patients has begun in the extension of the trial intended to extend the safety data for the BioCardia intramyocardial delivery catheter system.

South San Francisco, CA., July 31st, 2007

BioCardia announces that the patients enrolled in the initial cohort of the
TABMMI trial have all reached their two year followup and are doing well.
The Investigators will be submitting the two year follow-up clinical data
for peer reviewed publication in coming months.

BioCardia has extended this safety trial and enrollment has been initiated
with anticipated completion before the end of the year. For more
information on this extended trial please see the National Institute of
Health website www.clinicaltrials.gov.

About BioCardia
Formed in 1999, BioCardia, Inc. is a leader in the development of catheter
systems which enable local delivery of therapeutics to the heart and other
organs. BioCardia currently is marketing the BioCardia Morph® Deflectable
Tip Guide Catheter. Biotherapeutic clinical trials are ongoing using
BioCardia's Helical Infusion System to deliver cell, gene, and protein
therapies directly to the heart muscle. For more information, contact:
Investor Relations, BioCardia, Inc. 650-624-0900, .